Rigel Pharmaceuticals (RIGL) Current Assets (2010 - 2026)

Rigel Pharmaceuticals' Current Assets history runs 17 years deep, the most recent figure standing at $234.0 million for Q1 2026.

• On a quarterly basis, Current Assets rose 59.68% year-over-year to $234.0 million in Q1 2026; TTM through Mar 2026 was $234.0 million, a 59.68% increase from a year earlier, with the FY2025 full-year figure at $240.2 million, up 77.77% from the prior year.
• Current Assets declined to $234.0 million in Q1 2026 per RIGL's latest filing, from $240.2 million in the prior quarter.
• Across five years, Current Assets topped out at $240.2 million in Q4 2025 and bottomed at $92.5 million in Q1 2024.
• The 5-year median for Current Assets is $115.9 million (2022), against an average of $136.9 million.
• Across the five-year window, Current Assets slumped 35.45% in 2022 and soared 101.87% in 2025, its largest moves.
• Year by year, Current Assets stood at $115.9 million in 2022, then retreated by 14.35% to $99.3 million in 2023, then soared by 36.1% to $135.1 million in 2024, then jumped by 77.77% to $240.2 million in 2025, then fell by 2.56% to $234.0 million in 2026.
• Per Business Quant, the three latest RIGL Current Assets figures stand at $234.0 million (Q1 2026), $240.2 million (Q4 2025), and $214.9 million (Q3 2025).